M Ventures

Corporate venture capital fund that invests in biotechs.

Profile being verified

Stage
Series A to Series C across recorded rounds
Ticket
Tickets not disclosed; recorded rounds of USD 50 M to USD 135 M
Location
Not specified
Tracked rounds
2

What they look for

Co-led Nouscom's round with Revelation Partners; existing investor in FoRx Therapeutics. Hakan Goker, managing director and head of biotech investments, is quoted.

Recent investments

Recorded Swiss rounds: FoRx Therapeutics (Series A, USD 50 M, December 2025), Nouscom (Series C, USD 135 M, October 2026, co-lead).

Rounds tracked by FundSwiss